From the website 17/12, page-2

Pretty good results from what I can see.

With immunotherapies it can take a while until patients respond. Normally they start to get worse before improving.

Half had partial response. The term is a bit misleading as it means in this case a reduction in tumor size of above 30%, so it could be 70%.

Stable disease is also good, as it means that their tumor growth has slowed (or could even have reduced), as this is for those with a change of between a 30% reduction and 20% increase.

And of course the patients produce their own antibodies, probably forever now - so there's certainly hope for them being cured eventually.

So B cells are showing that they are effective, they are cheap to produce and there are no safety issues at all so far.

Any large pharmas might find this all very interesting too, especially as immunotherapies are expected to top $100b in sales per year soon. Perhaps a deal with large back-end payments? Especially given the big safety issues that some of the biggest selling immunotherapies have.